NF1 is a RAS GTPase-activating protein that regulates nucleotide cycling; if inactivated, carcinogenesis ensues. Although NF1 mutations are known to occur in NSCLC (5–11%), NF1-mutant NSCLC has yet to be genomically profiled. There is also a paucity of data about the response of this subgroup to immune checkpoint inhibitors. Investigators sought to address these gaps.
To characterise the genomic landscape of NF1-mutant NSCLC, Dr Marcelo Negrao (MD Anderson Cancer Center, TX, USA) and colleagues utilised the FMI FoundationCore NSCLC database, which had >4,500 samples covering the NF1-mutant variant. NF1 alterations were assessed for functionality using a proprietary artificial intelligence-based algorithm. Genomic profiling for all samples was performed via next-generation targeted panel sequencing, and PD-L1 expression was assessed via Dako 22C3 assay. Highlights of their findings included:
- Loss-of-function NF1 mutations were prevalent in NSCLC
- NF1-mutant lung adenocarcinomas (LUAD) were positively enriched for TP53 mutations, and negatively enriched for oncogene alterations
- Co-alterations in TP53 and/or CDKN2A/B were highly prevalent in NF1-mutant LUAD and nearly universal in NF1-mutant lung squamous cell carcinomas (LUSC)
- NF1-mutant non-squamous NSCLC were significantly enriched for high TMB
- NF1-mutant non-squamous NSCLC were significantly enriched for high PD-L1 expression
To assess PFS outcomes achieved with single-agent PD-1/PDL-1 inhibitors, the investigators leveraged the publicly availably OAK/POPLAR (n=765) and Rizvi cohort (n=185) databases. In both cohorts, they found that NF1-mutant/high TMB NSCLC had prolonged PFS as compared with NF1-wild type/high TMB NSCLC.
The investigators concluded that their findings demonstrate the impact of cancer gene mutations and the influence of TMB on clinical outcomes. NF1-mutant/high TMB NSCLC seem to be highly sensitive to immune checkpoint inhibitors.
- Negrao M. Genomic landscape and clinical outcomes with immune checkpoint inhibitors in NF1-mutant NSCLC. MA 09.07, WCLC 2021, 8–14 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« New preoperative classification scheme proposed for oligometastatic NSCLC Next Article
Baseline CD8+ T-cells predict NSCLC immunotherapy safety »
« New preoperative classification scheme proposed for oligometastatic NSCLC Next Article
Baseline CD8+ T-cells predict NSCLC immunotherapy safety »
Table of Contents: WCLC 2021
Featured articles
Atezolizumab promising for treating NSCLC brain metastases
Novel Therapy Approaches
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
COVID-19
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Evidence-Based Advocacy
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Response Predictors
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
Related Articles
November 26, 2019
Frontline ipilimumab/nivolumab improves OS in advanced NCLSC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com